Ascendis Pharma A (ASND) Securities (2020 - 2023)

Ascendis Pharma A (ASND) has 4 years of Securities data on file, last reported at $7.8 million in Q4 2023.

• For the quarter ending Q4 2023, Securities fell 97.36% year-over-year to $7.8 million; the trailing twelve-month figure through Dec 2023 stood at $7.8 million (down 97.36% YoY), and the FY2023 full-year result was $7.9 million, down 97.43% from the prior year.
• Securities fell to $7.8 million in Q4 2023, from $15.4 million in the prior quarter.
• In the past five years, Securities ranged from a high of $314.1 million in Q3 2022 to a low of $7.8 million in Q4 2023.
• A 4-year average of $186.3 million and a median of $200.0 million in 2021 frame the typical range for Securities.
• Across the five-year window, Securities surged 68.49% in 2021 and plunged 97.36% in 2023, its largest moves.
• Tracing ASND's Securities over 4 years: stood at $160.1 million in 2020, then surged by 68.49% to $269.7 million in 2021, then gained by 9.95% to $296.6 million in 2022, then sank by 97.36% to $7.8 million in 2023.
• Business Quant data shows ASND's Securities at $7.8 million in Q4 2023, $15.4 million in Q3 2023, and $40.2 million in Q2 2023.